Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
compound lactobacillus acidophilus
- Development stage
- Unknown
- Lead developer
- Tonghua Jinma Pharmaceutical Group
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Compound lactobacillus acidophilus is a combination probiotic formulation composed of four bacterial strains: Chinese strain Lactobacillus acidophilus, Japanese strain Lactobacillus acidophilus, Streptococcus faecalis (Enterococcus faecalis), and Bacillus subtilis. It is used as an intestinal flora regulator to treat disorders caused by dysbiosis such as mild acute diarrhea and functional bowel disturbances. The mechanism involves the breakdown of carbohydrates to produce lactic acid, which increases intestinal acidity and inhibits the growth of pathogenic bacteria. Clinical studies also suggest it can improve outcomes in Helicobacter pylori eradication therapy and relieve constipation by modulating gut microbiota composition[1][4][5][6].
- Brand names
- 益君康
- Other names
- 复方嗜酸乳杆菌片Compound Eosinophil-Lactobacillus TabletsFufang Shisuanruganjun Pian
02
Targets
CEACAM6
Beyond the preview
Go deeper on compound lactobacillus acidophilus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on compound lactobacillus acidophilus.